Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159(1):139-144 | DOI: 10.5507/bp.2014.054

Hepatic arterial infusion in hepatocellular carcinoma: a single center experience

Bohuslav Melichara,f, Josef Dvorakc, Alexander Ferkob, Katerina Kamaradovad, Antonin Krajinae
a Department of Oncology, Faculty of Medicine and Dentistry, Palacky University Olomouc, Czech Republic
b Department of Surgery, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove
c Department of Oncology and Radiotherapy, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove
d The Fingerland Institute of Pathology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove
e Department of Radiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove
f 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Kralove, Charles University in Prague and University Hospital Hradec Kralove

Aim: The aim of the present study was to evaluate a single center experience with hepatic arterial infusion (HAI) in patients with hepatocellular carcinoma.

Methods: A retrospective analysis of 20 patients treated for hepatocellular carcinoma between 1994 and 2007.

Results: Most patients were treated with an HAI of doxorubicin and cisplatin combined with 5-fluorouracil and folinic acid. The response was not evaluable in the majority of patients, predominantly because of associated surgical procedure or because only one cycle of HAI was administered. The median progression-free survival was 7.7 months. The median survival of all patients was 12.2 months (5-year survival 5%). Serious adverse events were observed in 5 patients, and one patient died of liver failure in association with the administration of HAI.

Conclusion: The data show the limited efficacy of HAI in patients with hepatocellular carcinoma.

Keywords: hepatic arterial infusion, hepatocellular carcinoma

Received: May 28, 2014; Accepted: October 8, 2014; Prepublished online: November 11, 2014; Published: March 9, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Melichar, B., Dvorak, J., Ferko, A., Kamaradova, K., & Krajina, A. (2015). Hepatic arterial infusion in hepatocellular carcinoma: a single center experience. Biomedical papers, 159(1), 139-144. doi: 10.5507/bp.2014.054
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Han KH, Kudo M, Ye SL, Choi JY, Poon RT, Seong J, Park JW, Ichida T, Chung JW, Chow P, Cheng AL. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology 2011;81:158-64. Go to original source... Go to PubMed...
    2. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011;61:69-90. Go to original source... Go to PubMed...
    3. Fraker DL, Soulen M. Regional therapy of hepatic metastases. Hem Oncol Clin N Am 2002;16:947-67. Go to original source...
    4. Melichar B. Hepatic arterial infusion in colorectal carcinoma: Is anatomical targeting still relevant in an era of molecularly-targeted therapy? Biomed Pap Med Fac Univ Palacky Olomouc Czech Rep 2012;156:81-92. Go to original source... Go to PubMed...
    5. Melichar B, Voboril Z, Lojik M, Krajina A. Liver metastases from uveal melanoma: clinical experience of hepatic arterial infusion of cisplatin, vinblastine and dacarbazine. Hepatogastroenterology 2009;56:1157-62. Go to PubMed...
    6. Melichar B, Voboril Z, Dvorak J, Ferko A, Rozkos T, Krajina A. Hepatic arterial infusion for biliary tract carcinoma: single-center experience. Anticancer Res 2013;33:1201-8.
    7. Llovet JM, Bruix J. Systemic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 2003;37:429-42. Go to original source... Go to PubMed...
    8. Park JY, Ahn SH, Yoon YJ, Kim JK, Lee HW, Lee do Y, Chon CY, Moon YM, Han KH. Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer 2007;110:129-37. Go to original source... Go to PubMed...
    9. Baek YH, Kim KT, Lee SW, Jeong JS, Park BH, Nam KJ, Cho JH, Kim YH, Roh YH, Lee HS, Choi YM, Han SY. Efficacy of hepatic arterial infusion chemotherapy in advanced hepatocellular carcinoma. World J Gastroenterol 2012;18:3426-34. Go to original source... Go to PubMed...
    10. Yamasaki T, Sakaida I. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma and future treatments for the poor responders. Hepatol Res 2012 42:340-8. Go to original source... Go to PubMed...
    11. Ueda H, Fukuchi H, Tanaka C. Toxicity and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma (Review). Oncol Lett 2012;3:259-63. Go to original source... Go to PubMed...
    12. Shao YY, Huang CC, Liang PC, Lin ZZ. Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2010;6:80-8. Go to original source... Go to PubMed...
    13. Yamashita T. Current status of hepatocellular carcinoma treatment in Japan. Clin Drug Investig 2012;32:15-23. Go to original source... Go to PubMed...
    14. Nouso K, Miyahara K, Uchida D, Kuwaki K, Izumi N, Omata M, Ichida T, Kudo M, Ku Y, Kokudo N, Sakamoto M, Nakashima O, Takayama T, Matsui O, Matsuyama Y, Yamamoto K. Effect of hepatic arterial infusion chemotherapy of 5-fluorouracil and cisplatin for advanced hepatocellular carcinoma in the Nationwide Survey of Primary Liver Cancer in Japan. Br J Cancer 2013;109:1904-7. Go to original source... Go to PubMed...
    15. Kirikoshi H, Yoneda M, Mawatari H, Fujita K, Imajo K, Kato S, Suzuki K, Kobayashi N, Kubota K, Maeda S, Nakajima A, Saito S. Is hepatic arterial infusion chemotherapy effective treatment for advanced hepatocellular carcinoma resistant to transarterial chemoembolization? World J Gastroenterol 2012;18:1933-9. Go to original source... Go to PubMed...
    16. Kim BK, Park JY, Choi HJ, Kim do Y, Ahn SH, Kim JK, Lee do Y, Lee KH, Han KH. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma. J Cancer Res Clin Oncol 2011;137:659-67. Go to original source... Go to PubMed...
    17. Yamashita T, Arai K, Sunagozaka H, Ueda T, Terashima T, Yamashita T, Mizukoshi E, Sakai A, Nakamoto Y, Honda M, Kaneko S. Randomized, phase II study comparing interferon combined with hepatic arterial infusion of fluorouracil plus cisplatin and fluorouracil alone in patients with advanced hepatocellular carcinoma. Oncology 2011;81:281-90. Go to original source... Go to PubMed...
    18. Okusaka T, Kasugai H, Shioyama Y, Tanaka K, Kudo M, Saisho H, Osaki Y, Sata M, Fujiyama S, Kumada T, Sato K, Yamamoto S, Hinotsu S, Sato T. Transarterial chemotherapy alone versus transarterial chemoembolization for hepatocellular carcinoma: a randomized phase III trial. J Hepatol 2009;51:1030-6. Go to original source... Go to PubMed...
    19. Miyaki D, Aikata H, Honda Y, Naeshiro N, Nakahara T, Tanaka M, Nagaoki Y, Kawaoka T, Takaki S, Waki K, Hiramatsu A, Takahashi S, Ishikawa M, Kakizawa H, Awai K, Chayama K. Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma according to Child-Pugh classification. J Gastroenterol Hepatol 2012;27:1850-7. Go to original source... Go to PubMed...
    20. Woo HY, Bae SH, Park JY, Han KH, Chun HJ, Choi BG, Im HU, Choi JY, Yoon SK, Cheong JY, Cho SW, Jang BK, Hwang JS, Kim SG, Kim YS, Seo YS, Yim HJ, Um SH. A randomized comparative study of high-dose hepatic arterial infusion chemotherapy for intractable, advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2010;65:373-82. Go to original source... Go to PubMed...
    21. Patt YZ, Charnsangavej C, Yoffe B, Smith R, Lawrence D, Chuang V, Carrasco H, Roh M, Chase J, Fischer H. Hepatic arterial infusion of floxuridine, leucovorin, doxorubicin, and cisplatin for hepatocellular carcinoma: Effects of hepatitis B and C viral infection on drug toxicity and patient survival. J Clin Oncol 1994;12:1204-11. Go to original source... Go to PubMed...
    22. Tzoracoleftherakis EE, Spiliotis JD, Kyriakopoulou T, Kakkos SK. Intra-arterial versus systemic chemotherapy for non-operable hepatocellular carcinoma. Hepatogastroenterology 1999;46:1122-5. Go to PubMed...
    23. Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T. Review of current staging systems for hepatocellular carcinoma. Hepatol Res 2007;37:S210-S215. Go to original source... Go to PubMed...
    24. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004;10:S115-S120. Go to original source... Go to PubMed...
    25. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14. Go to original source... Go to PubMed...
    26. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90. Go to original source... Go to PubMed...
    27. Bruix J, Sala M, Llovet JM. Chemoembolization for hepatocellular carcinoma. Gastroenterology 2004;127:S179-S188. Go to original source... Go to PubMed...
    28. Leung TWT, Johnson PJ. Systemic therapy for hepatocellular carcinoma. Semin Oncol 2001;28:514-20. Go to original source... Go to PubMed...
    29. Kudo M. Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy. Liver Cancer 2012;1:62-70. Go to original source... Go to PubMed...
    30. Sakon M, Nagano H, Dono K, Nakamori S, Umeshita K, Yamada A, Kawata S, Imai Y, Iijima S, Monden M. Combined intraarterial 5-fluorouracil and subcutaneous interferon-alpha therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002;94:435-42. Go to original source... Go to PubMed...
    31. Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-alpha-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998;55:39-47. Go to original source... Go to PubMed...
    32. Terashima T, Yamashita T, Arai K, Sunagozaka H, Kitahara M, Nakagawa H, Kagaya T, Mizukoshi E, Honda M, Kaneko S. Feasibility and efficacy of hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma after sorafenib. Hepatol Res 2014; 44:1179-85. doi:10.1111/hepr.12266. Go to original source... Go to PubMed...
    33. Shao YY, Liang PC, Wu YM, Huang CC, Huang KW, Cheng JC, Hsu CH, Hsu C, Cheng AL, Lin ZZ. A pilot study of hepatic arterial infusion of chemotherapy for patients with advanced hepatocellular carcinoma who have failed anti-angiogenic therapy. Liver Internat 2013;33:1413-9. Go to original source...
    34. Miyaki D, Aikata H, Kan H, Fujino H, Urabe A, Masaki K, Fukuhara T, Kobayashi T, Naeshiro N, Nakahara T, Kawaoka T, Hiramatsu A, Takahashi S, Ishikawa M, Kakizawa H, Awai K, Chayama K. Clinical outcome of sorafenib treatment in patients with advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy. J Gastroenterol Hepatol 2013;28:1834-41. Go to original source... Go to PubMed...
    35. Jeong SW, Jang JY, Lee JE, Lee SH, Kim SG, Cha SW, Kim YS, Cho YD, Kim HS, Kim BS, Kim KH, Kim YJ. The efficacy of hepatic arterial infusion chemotherapy as an alternative to sorafenib in advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 2012;8:164-71. Go to original source... Go to PubMed...
    36. Melichar B, Dvorak J, Hyspler R, Zadak Z. Intestinal permeability in the assessment of intestinal toxicity of cytotoxic agents. Chemotherapy 2005;51:336-8. Go to original source... Go to PubMed...
    37. Melichar B, Nemcová I. Eye complications of cetuximab therapy. Eur J Cancer Care 2007;16:439-43. Go to original source... Go to PubMed...
    38. Earlam S, Glover C, Davies M, Fordy C, Allen-Mersh TG. Effect of regional and systemic fluorinated pyrimidine chemotherapy on quality of life in colorectal liver metastasis patients. J Clin Oncol 1997;15:2022-9. Go to original source... Go to PubMed...
    39. Melichar B. Laboratory medicine and medical oncology: the tale of two Cinderellas. Clin Chem Lab Med 2013;51:99-112. Go to original source... Go to PubMed...
    40. Melichar B, Solichova D, Melicharova K, Malirova E, Cermanova M, Zadak Z. Urinary neopterin in patients with advanced colorectal carcinoma. Int J Biol Markers 2006;21:190-8. Go to original source... Go to PubMed...
    41. Melichar B, Jandik P, Krejsek J, Solichova D, Drahosova M, Skopec F, Mergancova J, Voboril Z. Mitogen-induced lymphocyte proliferation and systemic immune activation in cancer patients. Tumori 1996;82:218-20. Go to PubMed...
    42. Melichar B, Touskova M, Solichova D, Kralickova P, Kopecky O. CD4+ T-lymphocytopenia and systemic immune activation in patients with primary and secondary liver tumours. Scand J Clin Lab Inv 2001;61:363-70. Go to original source... Go to PubMed...
    43. Fagan EA, Pulley M, Limb A, Wolstencroft R, Cranenburgh C, De Vinci C, Karani J, Michell M, Nunnerley H, Zaman S. Adoptive immunotherapy administered via the hepatic artery and intralesional interleukin-2 in hepatocellular carcinoma. Cancer Treat Rev 1989;16:151-60. Go to original source... Go to PubMed...
    44. Takayama T, Sekine T, Makuuchi M, Yamasaki S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi Y, Kakizoe T. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomized trial. Lancet 2000;356:802-7. Go to original source... Go to PubMed...
    45. Oka M, Hazama S, Yoshino S, Shimoda K, Suzuki M, Shimizu R, Yano K, Nishida M, Suzuki T. Intraarterial combined immunochemotherapy for unresectable hepatocellular carcinoma: preliminary results. Cancer Immunol Immunother 1994;38:194-200. Go to original source...

    Return to the content